当前位置:药药网 / 数据中心 / 儿科标签更改电子表格2021
Viibryd
通用名称
vilazodone hydrochloride
儿科标签批准日期
2020/1/31 0:00:00
特定指示/秒
Major depressive disorder (MDD)
标签更改摘要
- Safety and effectiveness have not been established in pediatric patients for the treatment of MDD.
- Efficacy was not demonstrated in two adequate and well controlled, 8-week studies including a total of 1002 pediatric patients ages 7
- years to 17 years of age with MDD. The following adverse reactions were reported in at least 5% of pediatric patients treated with
- VIIBRYD and occurred at a rate at least twice that for pediatric patients receiving placebo: nausea, vomiting, diarrhea, abdominal
- pain/discomfort, and dizziness.
- Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric patients